What is the settlement amount Moderna agreed to pay?

Moderna has agreed to a lump sum payment of $950 million to resolve global litigation.

Will Moderna owe future royalties after this settlement?

No, the settlement agreement ensures that Moderna will not owe any future royalties on its infectious disease portfolio.

What is Moderna's projected year-end cash balance for 2026?

Moderna expects to end 2026 with cash and cash equivalents in the range of $4.5 to $5.0 billion.

Home / Business and Economy / Moderna Settles Lawsuit for $950M, Eyes Future Growth

Moderna Settles Lawsuit for $950M, Eyes Future Growth

5 Mar

•

Summary

Moderna agrees to a $950 million payment to settle global litigation.
No future royalties will be paid on its infectious disease portfolio.
Year-end cash is projected between $4.5 to $5.0 billion.

Moderna Settles Lawsuit for $950M, Eyes Future Growth

Moderna announced on March 3, 2026, a significant settlement agreement resolving all global litigation with Arbutus Biopharma Corporation and Genevant Sciences GmbH. This settlement, which includes disputes in the U.S. District Court for the District of Delaware, pertains to Spikevax(R) and mRESVIA(R).

Under the terms, Moderna will pay a lump sum of $950 million in the third quarter of 2026, with no future royalties owed. The company plans to appeal a District Court's Section 1498 decision, potentially avoiding an additional payment of up to $1.3 billion if successful. A charge of $950 million is expected in Q1 2026.

Following the settlement, Moderna forecasts its 2026 year-end cash and cash equivalents to be between $4.5 to $5.0 billion. CEO Stéphane Bancel stated this resolves a legacy matter, allowing focus on future growth and product approvals, including flu vaccines. The company also anticipates favorable results from therapeutic trials in cancer and rare diseases.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.